ENSC Stock - Ensysce Biosciences, Inc.
Unlock GoAI Insights for ENSC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $5.21M | $2.23M | $2.52M | $3.53M | $3.93M |
| Gross Profit | $-2,009,405 | $-5,357,000 | $-17,312,492 | $3.53M | $3.93M |
| Gross Margin | -38.6% | -240.1% | -686.1% | 100.0% | 100.0% |
| Operating Income | $-6,730,000 | $-10,718,000 | $-24,222,095 | $-19,870,431 | $-1,613,287 |
| Net Income | $-7,987,000 | $-10,613,000 | $-24,172,292 | $-29,083,711 | $56,770 |
| Net Margin | -153.3% | -475.7% | -957.9% | -823.6% | 1.4% |
| EPS | $-4.57 | $-4.69 | $-139.44 | $-355.68 | $0.56 |
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Visit WebsiteEarnings History & Surprises
ENSCEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 9, 2026 | $-0.99 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.85 | $-1.29 | -51.8% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-1.02 | $-0.79 | +22.5% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-3.02 | $-1.39 | +54.0% | ✓ BEAT |
Q1 2025 | Mar 10, 2025 | $-2.74 | $-2.90 | -5.8% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-4.50 | $1.05 | +123.3% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-5.85 | $-3.30 | +43.6% | ✓ BEAT |
Q2 2024 | May 10, 2024 | $-13.49 | $-8.25 | +38.8% | ✓ BEAT |
Q1 2024 | Mar 15, 2024 | $-12.89 | $-16.94 | -31.4% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-15.89 | $-13.04 | +17.9% | ✓ BEAT |
Q3 2023 | Aug 11, 2023 | $-40.93 | $-14.69 | +64.1% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-208.55 | $-31.18 | +85.0% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-466.15 | $-273.57 | +41.3% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-539.95 | $-923.31 | -71.0% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-755.92 | $-863.91 | -14.3% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-719.93 | $-719.93 | 0.0% | = MET |
Q1 2022 | Mar 31, 2022 | $323.97 | $-1619.84 | -600.0% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | — | $-2555.74 | — | — |
Q3 2021 | Aug 16, 2021 | — | $-215.98 | — | — |
Latest News
Watching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45 Price Valuation
📈 PositiveEnsysce Biosciences Announces First Patient Enrolled In Co's Pivotal Phase 3 Clinical Trial Of PF614
📈 PositiveEnsysce Biosciences Receives U.S. Patent And Trademark Office Notice Of Allowance For New Patent Covering Multi-Pill Abuse Resistance Technology
📈 PositiveEnsysce Biosciences Announces FDA Agrees With Ensysce's Proposed Plans On Approach To Manufacture PF614
📈 PositiveWatching Ensysce Biosciences; Zacks Small-Cap Research Gives Stock $16.45 Price Valuation
📈 PositiveEnsysce Biosciences Secures $4M Financing To Accelerate Phase 3 Development Of PF614 And Advance Abuse- And Overdose-Resistant Pain Therapies
📈 PositiveEnsysce Biosciences Q3 EPS $(1.29) Misses $(0.84) Estimate, Sales $493.104K Miss $700.000K Estimate
📉 NegativeEnsysce Biosciences Showcases TAAP and MPAR Platforms In PAINWeek2025 Symposium Highlights, Redefining Opioid Safety Amid Global Crisis
📈 PositiveEnsysce Biosciences Narrows Loss in Q2
📈 PositiveFrequently Asked Questions about ENSC
What is ENSC's current stock price?
What is the analyst price target for ENSC?
What sector is Ensysce Biosciences, Inc. in?
What is ENSC's market cap?
Does ENSC pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ENSC for comparison